Novartis AG (NVS) Vaccine Division Hit by Bexsero Setback
7/24/2013 7:45:04 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Swiss drugmaker Novartis suffered a fresh blow to the turnaround prospects of its loss-making vaccines division as a key committee advised against including its meningitis B vaccine on Britain's routine vaccination program. The UK Joint Committee on Vaccination and Immunisation (JCVI) said on Wednesday that it had taken the interim decision not to recommend Bexsero because the vaccine is unlikely to prove cost-effective. Bexsero won European approval this year to become the first vaccine against "MenB", a bacterial infection that can kill in 24 hours and poses the greatest risk to infants.
Help employers find you! Check out all the jobs and post your resume.
comments powered by